Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase Ib dose allocation study of oral administration of lucitanib given in combination with fulvestrant in patients with oestrogen receptor-positive and FGFR1-amplified or non-amplified metastatic breast cancer

Next Previous
X
Search
Trial Profile

Phase Ib dose allocation study of oral administration of lucitanib given in combination with fulvestrant in patients with oestrogen receptor-positive and FGFR1-amplified or non-amplified metastatic breast cancer

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 03 Feb 2020

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fulvestrant (Primary) ; Lucitanib (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Acronyms INES
  • Sponsors Servier

    • Most Recent Events

    • 09 Dec 2017 Results presented at the 40th Annual San Antonio Breast Cancer Symposium
    • 09 Dec 2017 Status changed from recruiting to discontinued, according to results presented at the 40th Annual San Antonio Breast Cancer Symposium
    • 01 Apr 2014 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top